Paediatric & Neonatal Testing Kits Market
Market Insights on Paediatric & Neonatal Testing Kits covering sales outlook, demand forecast & up-to-date key trends
Paediatric & Neonatal Testing Kits Market : Global Industry Analysis 2016 - 2020 and Opportunity Assessment 2021 - 2031
Paediatric & Neonatal Testing Kits Market Overview
According to the latest research by Future Market Insights, the Paediatric & Neonatal Testing Kits Market is expected to witness robust growth with 4-5% CAGR during the forecast period from 2021 to 2031.
The Paediatric & Neonatal Testing Kits will show growth due to the rising organ transplants globally and an increased number of donors to support the recipients’ transplantation. Therefore, growth at a significantly high CAGR will be expected soon.
What is Driving the Demand for Paediatric & Neonatal Testing Kits
Paediatric & Neonatal testing refers to the process of taking a blood sample from and testing the sample to identify specific illnesses or conditions. The illnesses that are tested are genetic, metabolic, or endocrine disorders.
The specific conditions included in a new-born screening test are typically illnesses that are serious and rare and may not have symptoms right away. The purpose of testing is to identify these illnesses early before the baby develops symptoms and becomes sick and to treat the disease so that the baby remains healthy.
The test is usually done twice, once before the baby leaves the hospital after being born and then a second time in the baby’s physician’s office in the first 2 weeks of life.
According to a study, each year, almost all of the 4 million babies born in the United States experience new-born screening. Of these babies who undergo screening, about 4000 will test positive for a condition.
According to WHO, it is to be expected that, at least 500,000 HIV-infected infants will be born each year, most of them in low-income countries with generalized epidemics. Mother-to-child transmission of HIV accounts for the vast majority of the 2.3 million children under the age of 15 years who are estimated to be living with HIV, almost 90% of them in sub-Saharan Africa.
As per WHO facts, in 2006, 380,000 children aged under 15 years died of AIDS-related causes. Affordable treatments for opportunistic infections are becoming increasingly available but this is of little benefit to infants unless they can be diagnosed early.
Early diagnosis of HIV allows healthcare providers to offer optimal care and treatment of HIV infected children, assists in decision-making on infant feeding and avoids needless stress in mothers and families.
Which Factors are likely to Augment the Growth of the Paediatric & Neonatal Testing Kits Market
Increasing cases of allergies in infants and children are becoming a large factor for diagnosis. Allergy-related disorders are among the leading diagnoses of chronic diseases in children.
According to one study, 8-10% have asthma and 15-25% have allergic rhinitis (hay fever). Most of these birth defects have no immediate visible effects on a baby but, unless detected and treated early, can cause physical problems, mental retardation, and, in some cases, death.
A lot of babies are found to have metabolic disorders and in these cases, only an early diagnosis and proper treatment can make the difference. For rare diseases, neonatal testing represents a weapon for early detection.
The SARS-Cov-2 pandemic necessitates tailored recommendations addressing specific procedures for neonatal and paediatric transport of suspected or positive COVID-19 patients.
The U.S. and Canada Paediatric & Neonatal Testing Kits Market Outlook
U.S. and Canada will retain the top position in the market of Paediatric & Neonatal Testing Kits due to the pronounced government involvement in paediatric & neonatal testing.
According to the American Academy of Paediatrics each year, 4.1 million new-borns are screened for congenital disorders in the U.S. Of these, 4,000 infants are diagnosed as having a condition.
It is estimated another 1,000 infants that have conditions go undetected. The Canadian Task Force on Preventive Health recommends that all children and teens age 17 years and younger have their growth monitored during primary care visits.
According to the U.S. Centres for Disease Control and Prevention, TB in children is a public health concern because it is a marker for recent transmission of the bacteria, and infants and young children are more likely than older children and adults to develop life-threatening forms of the disease.
Among children, the most cases of TB are seen in those under 5 years of age and adolescents older than 10 years of age. The American Academy of Paediatrics recommends that children who are at risk of contracting TB should have a tuberculin skin test.
Europe Demand Outlook for Paediatric & Neonatal Testing Kits
Europe is seeing growth in advancement in the healthcare sector and an increase in demand for better healthcare providing opportunities will lead the Paediatric & Neonatal Testing Kits market in Europe. There has been immense involvement of the government in paediatric and neonatal screening.
In 2004, the European Cystic Fibrosis Society (ECFS) established the Neonatal Screening Working Group (NSWG) to track current practices, support implementation, and establish consensus on issues arising in new-born screening.
It has been found that there has been a substantial increase and the adoption of Cystic Fibrosis New-born screening in Europe. Similarly, there have been steps taken by associations and governments in the region to promote Paediatric & Neonatal Testing. This will give rise to the market in the forecasted period.
Who are the Key Manufacturers and Suppliers of Paediatric & Neonatal Testing Kits
Some of the leading manufacturers and suppliers of Paediatric & Neonatal Testing Kits include
- PerkinElmer Inc.
- Trivitron Healthcare
- Natus Medical Incorporated
- Medtronic Plc
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories Inc
- , GE Healthcare
- ZenTech S.A.
- MP BIOMEDICALS
- Baebies, Inc.
- Masimo CareDx Inc.
- Thermo Fisher Scientific
- Hologic Inc.
- Eurofins Scientific
- JETA Molecular BV.
- ELITech Group SAS, Natera, Inc.
- F. Hoffmann-La Roche Ltd
- Biocare Health Resources Inc.
- Bio-Rad Laboratories, Inc.
- Biogenuix Medsystems Pvt Ltd
- Genome Diagnostics B.V.
- Sanbio B.V., and others.
These companies followed certain strategies like partnership, collaboration, product launch, and mergers and acquisitions to gain a good position in the market.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides an in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
- Assay kits & reagents
- Point of Care Testing
By Test Type:
- Dried Blood Spot
- Hearing Screening
- Critical Congenital Heart Defect (CCHD)
- Tandem Mass Spectrometry
- Pulse Oximetry
- Enzyme-based assays
- DNA based assays
By End User:
- Diagnostic Centres
- Maternity & Specialty Clinics
- North America
- Latin America
- South Asia
- East Asia